References
- Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and 5-fluorouracil as single agents and in combination for advanced squamous cell carsinoma of the head and neck. J Clin Oncol 1992; 10: 257–63.
- Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin, and vin-cristine (VABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin in recurrent or metastatic squamous cell carcinoma of head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5: 521–6.
- Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus 5-fluorouracil and carboplatin plus 5-fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck. A Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245–51.
- Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early clinical trials group. Ann Oncol 1994; 5: 533–9.
- Dreyfuss A, Clark J, Norris C, et al. Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996; 4: 1672–8.
- Forastiere A. Paclitaxel (Taxol) for the treatment of the head and neck cancer. Semin Oncol 1994; 21 (suppl 8): 49.
- Loeffler T, Freund W, Lipke J, Hausamen TU. Scheduled and dose intensified paclitaxel as weekly one-hour infusion in pretreated solid tumors: results of phase VII trial. Semin Oncol 1996; 23 (suppl 16): 32-4.
- Smith R, Thornton D, Allen J. A phase II trial of pacli-taxel in squamous cell carcinoma of the head and neck. Semin Oncol 1995; 22 (suppl 6): 41-6.
- Rowinsky E, Gilbert M, McGuire WP, et al. Sequences of Taxol and cisplatin: A phase I and pharmacokinetics study. J Clin Oncol 1992; 9: 1692–703.
- Hitt R, Hornedo J, Colomer R, et al. Study of escalat-ing doses of paclitaxel plus cisplatin in patients with inopera-ble head and neck cancer. Semin Oncol 1997; 24 (suppl 2): 58-64.
- Pinto H, Jacobs C. Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Clin N Am 1991; 5: 667–86.
- Verveij J, Alexiera-Figresch J, De Boer M. Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group. Eur J Cancer Clin Oncol 1998; 24: 795–6.
- Jacobs C, Meyers F, Hendrickson C, Kohler M, Carter S. A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck: a Northern California Oncology Group study. Cancer 1983; 52: 1563–9.
- Vogl S, Schoenfeld D, Kaplan BH, Lerner HJ, Engstrom PF, Horton J. A randomized prospective compari-son of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer 1985; 56: 432–42.
- Williams S, Velex-Garcia E, Essessee I, Ratkin G, Birch R, Einhorn LH. Chemotherapy for head and neck cancer: comparison of cisplatin + vinblastine + bleomycin versus methotrexate. Cancer 1986; 57: 18–23.
- Eisenberger M, Krasnow S, Ellenberg S, Silva H, Abrams J, Sinibaldi V. A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recur-rent and metastatic head and neck cancer. J Clin Oncol 1989; 7: 1341–5.
- Forastiere A, Urba S. Single agent paclitaxel and pacli-taxel plus ifosfamide in the treatment of head and neck can-cer. Semin Oncol 1995; 22: 24–7.
- Hanauske A, Schilling T, Heinrich BS, et al. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma. Semin Oncol 1995; 22 (suppl 14): 35-9.
- Thödtmann R, Theiss F, Kemmerich M, et al. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 1998; 9: 335–7.
- Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001; 19 (4): 1088–95.
- Hitt R, Paz-Ares L, Hidalgo M, et al. Phase I-II study of paclitaxel/cisplatin as a first line therapy for locally advanced head and neck cancer. Semin Oncol 1997; (suppl 19) 24: 19-24.
- Murphy B, Li Y, Cella D, Karnad A, Hussain M, Forastiere A. Phase III study comparing cisplatin & fluorouracil versus cisplatin & paclitaxel in metastatic/recurrent head and neck cancer. Proc Am Soc Clin Oncol 2001; 224a: 894.